Catalent to Discuss Innovative Approaches to Achieving T-Cell Commercial Readiness at Upcoming Industry Conference

Share Article

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Jesse Trekker, Ph.D., Business Director, Strategic Partnerships, Catalent Cell & Gene Therapy, will present at the Allogeneic Cell Therapies Summit, which will take place virtually on 26 – 28 October, 2020.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Jesse Trekker, Ph.D., Business Director, Strategic Partnerships, Catalent Cell & Gene Therapy, will present at the Allogeneic Cell Therapies Summit, which will take place virtually on 26 – 28 October, 2020.

On Monday, 26 Oct., at 12:30 p.m. EST, Dr. Trekker will present “How to Commercially Scale T-cell Allogeneic Therapies”, where he will consider ways to overcome scale up challenges to progress successful development programs. Dr. Trekker will also discuss Catalent’s custom manufacturing methodology, and approaches to accelerate T-cell therapies to commercial readiness, so that patients can benefit sooner from innovative new therapies.

Dr. Trekker joined Catalent through its acquisition of MaSTherCell in 2020. Prior to joining MaSTherCell, he worked as a valorization researcher at Imec. Dr. Trekker holds a master’s degree in biomedical sciences, and a doctorate in biomedical technology, both from the University of Leuven (KU Leuven), Belgium.

For more information, please visit http://www.catalent.com/events/allogeneic-cell-therapies-summit-2020/.

About Catalent Cell & Gene Therapy
With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling
Catalent
+447580041073
Email >

Richard Kerns
Visit website